Liperoti Rosa, Gambassi Giovanni, Lapane Kate L, Chiang Claire, Pedone Claudio, Mor Vincent, Bernabei Roberto
Centro di Medicina dell'Invecchiamento, Dipartimento di Scienze Gerontologiche, Geriatriche e Fisiatriche, Università Cattolica del Sacro Cuore, Rome, Italy. rosa_liperoti @rm.unicatt.it
J Clin Psychiatry. 2005 Sep;66(9):1090-6. doi: 10.4088/jcp.v66n0901.
Concern exists about a possible increased risk of cerebrovascular events (CVEs) among elderly patients receiving risperidone or olanzapine. We estimated the effect of atypical and conventional antipsychotics on the risk of CVEs among elderly nursing home patients with dementia.
We conducted a case-control study on residents of nursing homes in 6 U.S. states by using the Systematic Assessment of Geriatric drug use via Epidemiology database, which includes data from the Minimum Data Set linked to Medicare inpatient claims. Participants were diagnosed with Alzheimer's disease or other forms of dementia on the basis of clinical criteria and medical history (including medical records and neuroradiologic documentation). Cases included patients hospitalized for stroke or transient ischemic attack between June 30, 1998, and December 27, 1999. For each case, we identified up to 5 controls hospitalized for septicemia or urinary tract infection residing in the same facility during the same time period. The sample consisted of 1130 cases and 3658 controls.
After controlling for potential confounders, the odds ratio of being hospitalized for CVEs was 0.87 (95% CI = 0.67 to 1.12) for risperidone users, 1.32 (95% CI = 0.83 to 2.11) for olanzapine users, 1.57 (95% CI = 0.65 to 3.82) for users of other atypical agents, and 1.24 (95% CI = 0.95 to 1.63) for conventional antipsychotic users compared to nonusers of antipsychotics. A history of CVEs appeared to modify the effect of atypical antipsychotics other than risperidone on the risk of new events.
Overall, no increased risk of CVEs seems to be conferred by atypical or conventional antipsychotics. Preexisting cerebrovascular risk factors might interact with some atypical antipsychotics to increase the risk of events. These results should be interpreted in light of the limitations of the study and need to be confirmed.
对于接受利培酮或奥氮平治疗的老年患者,人们担心其脑血管事件(CVE)风险可能增加。我们评估了非典型和传统抗精神病药物对患有痴呆症的老年疗养院患者发生CVE风险的影响。
我们利用通过流行病学数据库进行的老年药物使用系统评估,对美国6个州疗养院的居民进行了一项病例对照研究,该数据库包括与医疗保险住院索赔相关的最低数据集的数据。参与者根据临床标准和病史(包括病历和神经放射学记录)被诊断为阿尔茨海默病或其他形式的痴呆症。病例包括1998年6月30日至1999年12月27日期间因中风或短暂性脑缺血发作住院的患者。对于每例病例,我们确定了多达5名同期在同一机构因败血症或尿路感染住院的对照。样本包括1130例病例和3658名对照。
在控制了潜在的混杂因素后,与未使用抗精神病药物的患者相比,使用利培酮的患者因CVE住院的比值比为0.87(95%CI = 0.67至1.12),使用奥氮平的患者为1.32(95%CI = 0.83至2.11),使用其他非典型药物的患者为1.57(95%CI = 0.65至3.82),使用传统抗精神病药物的患者为1.24(95%CI = 0.95至1.63)。CVE病史似乎改变了除利培酮以外的非典型抗精神病药物对新事件风险的影响。
总体而言,非典型或传统抗精神病药物似乎不会增加CVE风险。先前存在的脑血管危险因素可能与某些非典型抗精神病药物相互作用,增加事件风险。这些结果应结合研究的局限性进行解释,需要进一步证实。